{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"6.5","value":"2.83"},{"groupId":"OG001","lowerLimit":"2.0","upperLimit":"14.0","value":"2.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"ICR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"16.6","value":"2.79"},{"groupId":"OG001","lowerLimit":"2.0","upperLimit":"16.9","value":"2.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"title":"Investigator"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"description":"TRR was defined as the time from randomization to the first date that response criteria (CR or PR) were met, as determined by ICR and investigator assessment. Only participants who achieved an overall response were included in the analysis. For participants in the monotherapy arm who crossed over to combination therapy, disease assessments after crossover were not included in the TRR calculation.","dispersionType":"Full Range","groups":[{"description":"Obinutuzumab 1000 milligrams (mg) intravenously on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2 to 6; and then every 8 weeks for an additional 24 months or until disease progression. Each treatment cycle was 28 days.","id":"OG000","title":"Obinutuzumab"},{"description":"Zanubrutinib 160 mg twice a day orally with or without food and obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2 to 6, and then every 8 weeks for an additional 24 months or until disease progression. Each treatment cycle was 28 days.","id":"OG001","title":"Zanubrutinib + Obinutuzumab"}],"paramType":"MEDIAN","populationDescription":"ITT Analysis Set. Only participants who achieved an overall response were included in the analysis.","reportingStatus":"POSTED","timeFrame":"From first dose to primary analysis data cutoff (08OCT2021) start of a new anticancer therapy, or the crossover date, whichever came first. Median follow-up was 12.45 months.","title":"Time to Response (TTR)","type":"SECONDARY","unitOfMeasure":"Months"}